当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Sujitra Wongkasemjit
Numerous innovations have taken place recently in the quickly developing field of structure-based drug design. The surge of genomic, proteomic, and structural data has opened numerous new targets and opportunities for the discovery of therapeutic leads. An overview of the structure-based drug design process is given in this article, with an emphasis on the selection of a target, evaluation of the targets. A large region of selective inhibitor identification of an interest target is called structure-based drug design. Numerous computational techniques have been developed since the three-dimensional structures of pharmacological targets, primarily proteins, became available to address the difficulties involved in the drug design process. The main parameters to determine the efficacy of new chemical inhibitors are drug-likeness, drug ability of the target protein, specificity, off-target binding, etc.